在患有慢性乙型肝炎的患者中,核胺类型的使用与代谢参数之间的关系
1Department of Internal Medicine, Section of Gastroenterology, Istanbul Medipol University Medical School, Sefakoy Hospital, Istanbul, Turkey. aysun.yakut@istanbul.edu.tr.
European review for medical and pharmacological sciences
|October 16, 2023
概括
慢性乙型肝炎 (CHB) 的核胺类比治疗对代谢综合征 (MetS) 参数产生影响. 医疗治疗影响了脂质概况和胰岛素耐药性,突出显示了CHB治疗和代谢健康之间的联系.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性乙型肝炎 (CHB) 用核胺类型的治疗可降低病毒载量,但不能消除肝硬化或肝细胞癌 (HCC) 的风险.
- 代谢综合征 (MetS) 是管理CHB患者的日益关注的问题.
- 了解CHB治疗和MetS之间的相互作用对于全面的患者护理至关重要.
研究的目的:
- 在接受核类模拟治疗的患者中,研究代谢综合征 (MetS) 和慢性乙型肝炎 (CHB) 之间的关系.
- 评估特定核类同类对MetS参数的影响.
- 评估CHB医疗治疗与代谢健康指标之间的关联.
主要方法:
- 一项对不活跃的HBsAg阳性CHB患者的比较研究,这些患者接受了核胺类同类药物 (恩特卡维尔,拉米武丁,特诺福维尔二氧化硫酸盐,特诺福维尔胺) 与未接受治疗的患者.
- 收集人口统计数据,脂质资料,血红蛋白A1c (HbA1c) 和HOMA-IR.
- 评估非侵入性肝纤维化指标 (APRI,福恩斯指数,FIB-4) 和肝硬化症的超声波分级.
主要成果:
- 与未接受治疗的患者相比,接受医疗治疗的患者的LDL,HDL和总胆固醇水平较低,但HOMA-IR值较高.
- 恩特卡维尔 (ETV) 用户表现出HbA1c水平升高.
- 诺福维尔双醇烟酸 (TDF) 用户的肝硬度指标得分明显更高.
结论:
- 对于CHB的医疗治疗,包括核胺类型,显著影响代谢综合征参数.
- 像ETV和TDF这样的特定药物可能对血糖控制和肝纤维化标志物产生不同的影响.
- 需要进一步的研究来优化CHB治疗策略,考虑到代谢健康影响.
相关概念视频
Biosynthesis of Nucleic Acids
56
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
56
Hepatic Drug Excretion: Influencing Factors
134
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
134
Nonlinear Pharmacokinetics: Causes of Nonlinearity
206
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
206
Nonlinear Pharmacokinetics: Overview
395
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
395
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
42
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
42
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K


